A 12-month prospective trial of inject and extend regimen for ranibizumab treatment of age-related macular degeneration

Toalster, Nicholas, Russell, Matthew and NG, Paul (2013) A 12-month prospective trial of inject and extend regimen for ranibizumab treatment of age-related macular degeneration. Retina, 33 7: 1351-1358. doi:10.1097/IAE.0b013e3182831265


Author Toalster, Nicholas
Russell, Matthew
NG, Paul
Title A 12-month prospective trial of inject and extend regimen for ranibizumab treatment of age-related macular degeneration
Journal name Retina   Check publisher's open access policy
ISSN 0275-004X
1539-2864
Publication date 2013-07-01
Year available 2013
Sub-type Article (original research)
DOI 10.1097/IAE.0b013e3182831265
Open Access Status DOI
Volume 33
Issue 7
Start page 1351
End page 1358
Total pages 8
Place of publication Philadelphia, United States
Publisher Lippincott Williams & Wilkins
Language eng
Subject 2731 Ophthalmology
Abstract PURPOSE: To evaluate the safety and efficacy of a strictly applied inject and extend protocol for ranibizumab treatment of age-related macular degeneration. METHODS: This is a prospective, multicenter, nonrandomized trial. Patients underwent standard induction with 3 intravitreal doses of 0.5 mg ranibizumab, each 1 month apart. Following this induction, patients were evaluated and received an injection at each visit. If they did not meet set criteria for signs of exudative disease the interval to the next visit was extended by 2 weeks and if exudative disease was present the interval was shortened by 2 weeks. RESULTS: Vision improved by 1.3 lines (P = 0.008); 26% gained ≥3 lines of vision, 74% lost no lines of vision, and 95% avoided loss of ≥3 lines of vision. CONCLUSION: This study shows that the Inject and Extend protocol is safe and efficacious for the treatment of age-related macular degeneration. Head-to-head studies are needed to compare directly with other regimens currently in use, as well as economic analysis to investigate the financial implications. Copyright
Formatted abstract
PURPOSE: To evaluate the safety and efficacy of a strictly applied inject and extend protocol for ranibizumab treatment of age-related macular degeneration.

METHODS: This is a prospective, multicenter, nonrandomized trial. Patients underwent standard induction with 3 intravitreal doses of 0.5 mg ranibizumab, each 1 month apart. Following this induction, patients were evaluated and received an injection at each visit. If they did not meet set criteria for signs of exudative disease the interval to the next visit was extended by 2 weeks and if exudative disease was present the interval was shortened by 2 weeks.

RESULTS: Vision improved by 1.3 lines (P = 0.008); 26% gained ≥3 lines of vision, 74% lost no lines of vision, and 95% avoided loss of ≥3 lines of vision.

CONCLUSION: This study shows that the Inject and Extend protocol is safe and efficacious for the treatment of age-related macular degeneration. Head-to-head studies are needed to compare directly with other regimens currently in use, as well as economic analysis to investigate the financial implications.
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2014 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 32 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 35 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 29 Nov 2013, 03:14:18 EST by System User on behalf of School of Medicine